Premium
CD30 and the NPM‐ALK fusion protein (p80) are differentially expressed between peripheral blood and bone marrow in primary small cell variant of anaplastic large cell lymphoma
Author(s) -
Awaya Norihiro,
Mori Shigehisa,
Takeuchi Hitoshi,
Mori Shigeo,
Sugano Yasuo,
Kamata Tamihiro,
Takeuchi Tsutomu,
Abe Toru
Publication year - 2002
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.10059
Subject(s) - anaplastic large cell lymphoma , cd30 , immunophenotyping , bone marrow , lymphoma , anaplastic lymphoma kinase , clone (java method) , pathology , large cell , large cell lymphoma , peripheral t cell lymphoma , immunostaining , cancer research , medicine , biology , t cell , immunology , flow cytometry , immunohistochemistry , cancer , immune system , adenocarcinoma , genetics , dna , malignant pleural effusion , lung cancer
The t(2;5)(p23;q35) translocation results in the formation of a unique chimeric NPM‐ALK protein (p80). Expression of this protein is considered to be one of the clinical features of anaplastic large cell lymphoma (ALCL). Recently recognized as one clinical subtype of ALCL, the small cell variant is prone to have a leukemic presentation. Although the small cell variant has been recognized as a subtype of ALCL, the clinical properties of this subtype, especially the immunophenotype of lymphoma cells in peripheral blood, have not yet been fully described. This report shows that neither CD30 nor p80 is detected by immunostaining in the predominant small cell malignant clone and also in large lymphoma cells in peripheral blood, while large cells and occasionally observed small cells in bone marrow were found to be positive for CD30 and p80. Our findings suggest that differential expression of CD30 and p80 between peripheral blood and bone marrow lymphoma cells is a property of the small cell variant of ALCL. Am. J. Hematol. 69: 200–204, 2002. © 2002 Wiley‐Liss, Inc.